Effects of Prolonged Dual Antiplatelet Therapy in ST-Segment Elevation vs. Non-ST-Segment Elevation Myocardial Infarction
Open Access
- 25 May 2021
- journal article
- research article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 85 (6), 817-825
- https://doi.org/10.1253/circj.cj-20-0704
Abstract
Background:The benefits and risks of prolonged dual antiplatelet therapy (DAPT) have not been studied extensively across a broad spectrum of acute coronary syndromes. In this study we investigated whether treatment effects of prolonged DAPT were consistent in patients presenting with ST-segment elevation myocardial infarction (STEMI) vs. non-STEMI (NSTEMI). Methods and Results:As a post hoc analysis of the SMART-DATE trial, effects of ≥12 vs. 6 months DAPT were compared among 1,023 patients presenting with STEMI and 853 NSTEMI patients. The primary outcome was a composite of recurrent myocardial infarction (MI) or stent thrombosis at 18 months after the index procedure. Compared with the 6-month DAPT group, the rate of the composite endpoint was significantly lower in the ≥12-month DAPT group (1.2% vs. 3.8%; hazard ratio [HR] 0.31, 95% confidence interval [CI] 0.12–0.77; P=0.012). The treatment effect of ≥12- vs. 6-month DAPT on the composite endpoint was consistent among NSTEMI patients (0.2% vs. 1.2%, respectively; HR 0.20, 95% CI 0.02–1.70; P=0.140; Pinteraction=0.718). In addition, ≥12-month DAPT increased Bleeding Academic Research Consortium (BARC) Type 2–5 bleeding among both STEMI (4.4% vs. 2.0%; HR 2.18, 95% CI 1.03–4.60; P=0.041) and NSTEMI (5.1% vs. 2.2%; HR 2.37, 95% CI 1.08–5.17; P=0.031; Pinteraction=0.885) patients. Conclusions:Compared with 6-month DAPT, ≥12-month DAPT reduced recurrent MI or stent thrombosis regardless of the type of MI at presentation.Keywords
This publication has 22 references indexed in Scilit:
- 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery DiseaseJournal of Invasive Cardiology, 2016
- Five-year outcomes of ST-elevation myocardial infarction versus non-ST-elevation acute coronary syndrome treated with biodegradable polymer-coated sirolimus-eluting stents: Insights from the CREATE trialJournal of Cardiology, 2016
- Clinical characteristics, management and 1-year outcomes of patients with acute coronary syndrome in Iran: the Iranian Project for Assessment of Coronary Events 2 (IPACE2)BMJ Open, 2015
- Long-Term Use of Ticagrelor in Patients with Prior Myocardial InfarctionThe New England Journal of Medicine, 2015
- Comparison of Outcomes After Percutaneous Coronary Intervention Among Different Coronary Subsets (Stable and Unstable Angina Pectoris and ST-Segment and Non-ST-Segment Myocardial Infarction)The American Journal of Cardiology, 2014
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsJournal of the American College of Cardiology, 2011
- Comparison of Angiographic and Other Findings and Mortality in Non–ST-Segment Elevation versus ST-Segment Elevation Myocardial Infarction in Patients Undergoing Early Invasive InterventionThe American Journal of Cardiology, 2010
- The Risk of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Bare-Metal and Drug-Eluting StentsJACC: Cardiovascular Interventions, 2009
- Clinical End Points in Coronary Stent TrialsJournal of the American College of Cardiology, 2007
- Comparison of Coronary Plaque Rupture Between Stable Angina and Acute Myocardial InfarctionJournal of the American College of Cardiology, 2004